Summary & Overview
HCPCS J3591: Unclassified Drug or Biological for ESRD on Dialysis
HCPCS Level II code J3591 identifies an unclassified drug or biological when provided for patients with end-stage renal disease receiving dialysis. Nationally, this code matters because it captures use and billing for agents without a specific HCPCS designation but that are clinically relevant to dialysis care, ensuring treatments are reported and potentially reimbursed when no alternative code exists. Payers commonly engaged in coverage and payment for dialysis-related pharmaceuticals include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare.
This publication explains the clinical context of J3591—administration of medications or biologics specific to ESRD management on dialysis—and outlines what readers can expect regarding billing and oversight. Topics covered include common payer coverage considerations, typical sites of service where J3591 is billed, how the code is used in service lines tied to dialysis care, and areas where coding specificity can affect claims processing. The report also highlights implications for capture of drug utilization when a product lacks a dedicated HCPCS Level II code and summarizes available documentation and billing practices.
Data not available in the input for detailed associated taxonomies, ICD-10 diagnosis mappings, related codes, and service line breakdowns is noted where applicable.
Billing Code Overview
HCPCS Level II code J3591 denotes an unclassified drug or biological used for end-stage renal disease (ESRD) on dialysis. The code is used to report administration of a medication or biological that does not have a specific HCPCS Level II code but is provided in the context of treating patients with ESRD receiving dialysis.
Service Type: Drug or biological administration for ESRD on dialysis
Typical Site of Service: Dialysis facility or outpatient dialysis setting
Clinical & Coding Specifications
Clinical Context
A patient with end-stage renal disease (ESRD) receiving maintenance hemodialysis in an outpatient dialysis center presents for a scheduled dialysis session. During the dialysis treatment the nephrology team administers an unclassified injectable drug or biological specifically indicated for management of an ESRD-related complication (for example a novel phosphate binder formulation given intravenously during dialysis or an investigational anemia agent delivered during the session) billed with HCPCS Level II code J3591. The clinical workflow includes verification of the physician order and indication, pharmacy preparation and labeling of the drug/biologic, documentation of lot number and dosage in the dialysis medication administration record, administration by the dialysis nurse during the dialysis treatment, monitoring for adverse reactions during and after administration, and recording of the administration and any modifier information for billing. Typical site of service is an outpatient hospital dialysis unit or free-standing dialysis center. The typical patient is an adult with ESRD on chronic hemodialysis who requires an adjunctive injectable therapy during dialysis for an ESRD-related indication such as refractory hyperphosphatemia, intradialytic hypotension requiring a biologic agent, or anemia management when standard agents are unsuitable.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
22 | Increased procedural services |